Abingworth, of London, named David Mayer a partner.

Acadia Pharmaceuticals Inc., of San Diego, elected Laura A. Brege to its board.

Addex Pharmaceuticals Ltd., of Geneva, elected Ray Hill to its board and appointed Laurent Massuyeau head of business development.

Adolor Corp., of Exton, Pa., named Eliseo Oreste Salinas senior vice president of research and development and chief medical officer, effective June 2.

Advanced Life Sciences Holdings Inc., of Chicago, appointed John L. Flavin chief financial officer.

Advaxis Inc., of North Brunswick, N.J., named Christine Chansky executive clinical officer.

Adventrx Pharmaceuticals Inc., of San Diego appointed Jose Hechavarria vice president of manufacturing.

Aegera Therapeutics Inc., of Montreal, appointed Jeremy Curnock Cook and Gary Littlejohn to its board.

AltheaDx Inc., of San Diego, appointed Cyrus Mirsaidi vice president of business development, sales and marketing.

Anavex Life Sciences Corp., of Geneva, appointed Dimitri Goundis project director of clinical development.

Aquapharm Biodiscovery Ltd., of Oban, Scotland, appointed Douglas Thomson commercial director and named Axel Kleemann to its board.

Ardea Biosciences Inc., of San Diego, appointed John W. Beck senior vice president of finance and operations and chief financial officer.

Avexa Ltd., of Melbourne, Australia, appointed Nathan Drona a nonexecutive director.

AVI BioPharma Inc., of Portland, Ore., appointed Ryszard "Richard" Kole senior vice president of discovery research.

BioNanomatrix Inc., of Philadelphia, appointed Paul R. Selvin to its scientific advisory board.

Bionovo Inc., of Emeryville, Calif., appointed John D. Baxter to its board.

Bioponic Phytoceuticals Inc., of Maui, Hawaii, named Barbara Anne Nabrit-Stephens to its scientific advisory board.

BioReliance Corp., of Rockville, Md., named Donna Klein vice president of human resources and John Ludwig Kolman senior director of research and development.

BioSante Pharmaceuticals Inc., appointed Michael C. Snabes vice president of clinical development.

Bioxel Pharma Inc., of Sainte-Foy, Quebec, appointed Thomas Warden vice president of sales, marketing and regulatory affairs.

BrainStorm Cell Therapeutics Inc., of New York, appointed Roscoe M. Moore Jr. to its advisory board.

Cardium Therapeutics, of San Diego, named Richard A. Schatz to its scientific advisory board.

Cell Therapeutics Inc., of Seattle, named Craig W. Philips president.

Cephalon Inc., of Frazer, Pa., appointed Jerry Pappert executive vice president and general counsel.

Cequent Pharmaceuticals, of Cambridge, Mass., named Michael D. Taylor to its board.

ChemGenex Pharmaceuticals, of Melbourne, Australia, named Luana Staiger vice president of regulatory affairs.